dMR During First Line Treatment of Non Squamous Lung Cancer: Time Course and Prognostic and Predictive Impact.

NCT02195336 · clinicaltrials.gov ↗

NA

Phase

UNKNOWN

Status

20

Enrollment

OTHER

Sponsor class

Conditions

Non-small Cell Lung Cancer

Interventions

DEVICE: dMRT
DRUG: Bevacizumab
DRUG: paclitaxel and carboplatin

Sponsor

Karl Kölbeck